FDA approves Takeda’s ENTYVIO SC for Crohn’s disease

2024-04-19
Pharmaceutical Technology
临床结果临床3期上市批准
The safety profile of Takeda’s TENTYVIO SC in the trial was aligned with the IV formulation. Credit: Michael Vi via Shutterstock.
The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy to treat adults with moderately to severely active Crohn’s disease (CD).
ENTYVIOFood and Drug Administration (FDA)enance treatment in moderately to sENTYVIO active CD patients following induction therapy using intravenous (IV) ENTYVIO.active Crohn’s disease (CD)
ENTYVIOember 2023, the FDA approved the SC administration of ENTYVIO as a maintenancactive CDnt in adults with moderately to severely active ulcerative coENTYVIOatients and is available as a single-dose prefilled pen (ENTYVIO Pen) in the US.
The latest approval is FDAed on the findings from the double-ENTYVIOrandomised, placebo-controlled Phase III VISIBLE 2 Study analysingactive ulcerative colitisof ENTYVIO SC.ENTYVIO
Trial data showed that a significant 48% of patients receiving ENTYVIO SC every two weeks achieved long-term clinical remission, compared to 34% of those on placeENTYVIO
See Also:ENTYVIO
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approval
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid TumorCancer: Likelihood of Approval
ENTYVIO SC’s safety profile in the trial was in line with the IV formulation, with injection site reactions noted as an adverse reaction.
Takeda USGuangzhou Huajin Pharmaceutical Technologyd heaPeritoneal Cancerid: “The approval of subcutaneous ENTYVIO in Crohn’s disease delivers on our goal of providing treatment options that can help patients achieve remission of their ulcerative colitis or Crohn’s disease, while also providing them flexibility and choice of route of administration.
“With ENTYVIO Pen, patients have the option of administering their maintenance treatment at home or on the go.
ENTYVIOvelopment of a subcutaneous option demonstrates Takeda’s commitment to meeting the very real needs of those living with gastrointestinal diseases.”
Last month, the Japanese Ministry of Health, Labour and Welfare approved the company’s ADZYNMA Intravenous ENTYVIOon 1Crohn’s diseasengenital thrombotic thrombocytopenic purpura.ulcerative colitisCrohn’s disease
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。